Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report

被引：9
|
作者：
Sun, Kunyan [1 ]
Nie, Ligong [1 ]
Nong, Lin [2 ]
Cheng, Yuan [1 ]
机构：
[1] Peking Univ First Hosp, Dept Resp & Crit Care Med, 8 Xishiku St, Beijing 100034, Peoples R China
[2] Peking Univ First Hosp, Dept Pathol, Beijing, Peoples R China
来源：
THORACIC CANCER | 2021年 / 12卷 / 12期
关键词：
alectinib; ALK rearrangement; crizotinib; non‐ small cell lung cancer; STRN‐ ALK; FUSION; IDENTIFICATION;
D O I：
10.1111/1759-7714.13983
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non-small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors has significantly prolonged the progression-free survival of patients with ALK gene-sensitive mutations. However, the response of patients with rare ALK rearrangements to tyrosine kinase inhibitors remains unknown. Here, we report a rare case of striatin (STRN)-ALK-positive NSCLC showing primary resistance to first-line therapy alectinib and limited clinical activity of crizotinib in the alectinib-resistant setting.
引用
收藏
页码：1927 / 1930
页数：4
相关论文
共 50 条
  • [1] Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib
    Nakanishi, Yoko
    Masuda, Shinobu
    Iida, Yuko
    Takahashi, Noriaki
    Hashimoto, Shu
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : E202 - E204
  • [2] Alectinib/crizotinibDevelopment of drug resistance in ALK-positive non-small cell lung cancer: case report
    [J]. Reactions Weekly, 2020, 1829 (1) : 23 - 23
  • [3] Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient A case report
    Thomas, Quentin Dominique
    Pautas, Marie
    Guilhaume, Marie-Noelle
    Fiteni, Frederic
    Ge, Tony
    Girard, Nicolas
    [J]. MEDICINE, 2021, 100 (43) : E27611
  • [4] A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature
    De Smedt, Fabian
    Dessy, Frederique
    Carestia, Luciano
    Baldin, Pamela
    Nana, Frank Aboubakar
    Clapuyt, Philippe
    Boon, Veronique
    Amant, Frederic
    Gziri, Mina Mhallem
    [J]. ONCOLOGY LETTERS, 2023, 25 (02)
  • [5] Alectinib/crizotinibAcquired resistance to alectinib and crizotinib in non-small cell lung cancer: case report
    [J]. Reactions Weekly, 2018, 1707 (1) : 23 - 23
  • [6] Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
    Hu, Yan
    Ren, Siying
    Wang, Ruoyao
    Han, Wei
    Xiao, Peng
    Wang, Li
    Yu, Fenglei
    Liu, Wenliang
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [7] Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
    Misawa, Kazuhito
    Nakamichi, Shinji
    Iida, Hiroki
    Nagano, Atsuhiro
    Mikami, Erika
    Tozuka, Takehiro
    Matsumoto, Masaru
    Miyanaga, Akihiko
    Noro, Rintaro
    Kubota, Kaoru
    Yamaguchi, Hiroki
    Seike, Masahiro
    [J]. ONCOTARGETS AND THERAPY, 2023, 16 : 65 - 69
  • [8] Alectinib/crizotinibDevelopment of resistance in non-small cell lung cancer: case report
    [J]. Reactions Weekly, 2016, 1616 (1) : 15 - 15
  • [9] Unveiling Hidden MET-Mediated Primary Alectinib Resistance in ALK-Positive Non-Small Cell Lung Cancer
    Le, A.
    Tyler, L.
    Davies, K.
    Kondo, K.
    Pacheco, J.
    Merrick, D.
    Aisner, D.
    Camidge, D. R.
    Doebele, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S555 - S556
  • [10] Alectinib in a patient with ALK-positive non-small lung cancer unable to swallow capsules
    Ishiura, Yoshihisa
    Nomura, Shosaku
    Ishii, Yuka
    Imai, Kai
    Nakahama, Kahori
    Sawai, Yusuke
    Tamaki, Takeshi
    Shimizu, Toshiki
    Miyashita, Naoyuki
    Ito, Tomoki
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (05) : 1283 - 1285
12345